Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0005 EUR | -.--% | -.--% | -.--% |
04-15 | Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding | CI |
2023 | Canntab Therapeutics Limited Provide an Update on Product Delivery | CI |
Business Summary
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cannabinoids and Terpenes
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 19/04/16 | |
President | 56 | 19/04/16 | |
Chief Tech/Sci/R&D Officer | - | 14/05/20 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 10/04/18 |
Frank Candido
IRC | Investor Relations Contact | 59 | 31/08/18 |
Eric Malinski
SAM | Sales & Marketing | - | 30/04/18 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
President | 56 | 19/04/16 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 10/04/18 |
Vitor Fonseca
BRD | Director/Board Member | 71 | 10/04/18 |
Chief Executive Officer | 63 | 19/04/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,909,159 | 33,562,159 ( 86.26 %) | 0 | 86.26 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+45.15% | 6.38B | |
-14.00% | 4.59B | |
+9.54% | 3.39B | |
-8.99% | 3.2B | |
-2.41% | 2.52B | |
+50.03% | 2B | |
-6.97% | 1.7B | |
-0.31% | 1.65B | |
-10.61% | 1.58B |
- Stock Market
- Equities
- PILL Stock
- TBF1 Stock
- Company Canntab Therapeutics Limited